Genus gains 25% after FY adjusted pretax profit beats estimates

Genus gains 25% after FY adjusted pretax profit beats estimates

Genus Inc. (GNUS) shares surged by 25% on Monday, September 2, 2025, following the release of its fiscal year (FY) 2025 earnings report. The company reported an adjusted pretax profit of $0.24 per share, which exceeded analysts' expectations of $0.16 per share. This quarterly earnings report represents an earnings surprise of +50.00% [2].

Revenue for the quarter ended July 2025 was $235.96 million, surpassing the Zacks Consensus Estimate by 4.14% and year-ago revenues of $182.58 million. The company has consistently beaten consensus revenue estimates over the past four quarters, demonstrating strong financial performance. Over the last four quarters, Genus has surpassed consensus EPS estimates four times [2].

The stock's recent performance has been mixed, with shares losing about 15.4% since the beginning of the year compared to the S&P 500's gain of 9.1%. Despite this, the company's earnings outlook remains positive. The current consensus EPS estimate for the coming quarter is $0.19 on $240.95 million in revenues, and for the current fiscal year, it is $0.75 on $939.54 million in revenues [2].

The Zacks Rank, which considers earnings estimate revisions, has assigned a Zacks Rank #5 (Strong Sell) to Genus shares, indicating that the stock is expected to underperform the market in the near future. However, this assessment is based on the unfavorable estimate revisions trend before the earnings report. The stock's immediate price movement will depend on management's commentary on the earnings call and the outlook for the industry [2].

Genus operates in the Internet - Software industry, which ranks in the top 27% of the 250 plus Zacks industries. The industry's performance has a material impact on the stock's performance. Another stock from the same industry, DocuSign (DOCU), is expected to report earnings for the quarter ended July 2025 on September 4, 2025. The results are expected to be released soon [2].

References:
[1] https://www.reuters.com/business/healthcare-pharmaceuticals/south-africas-aspen-aims-profit-turnaround-with-insulin-glp-1-drugs-2025-09-03/
[2] https://finance.yahoo.com/news/gitlab-inc-gtlb-q2-earnings-211503672.html
[3] https://www.tradingview.com/news/reuters.com,2025:newsml_L6N3UQ0CM:0-derichebourg-drops-on-fy-profit-target-cut/